Skip to main content
SpringerLink
Log in

Strategien zur Inhibition der Protein-aggregation bei Amyloidkrankheiten

  • Wissenschaft · Special: Molekulare Diagnostik/Labormedizin
  • Molekulare Medizin
  • Published:
BIOspektrum Aims and scope

Abstract

Aberrant protein aggregation into amyloid fibrils is linked to cell degeneration and the pathogenesis of a number of fatal diseases including Alzheimer’s disease and type 2 diabetes. Here biomolecular recognition principles and peptide-based strategies towards inhibition of protein aggregation and associated cell damage in these two yet incurable amyloid diseases are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Westermark P (2005) Aspects on human amyloid forms and their fibril polypeptides. FEBS J 272:5942–5949

    Article  PubMed  CAS  Google Scholar 

  2. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333–366

    Article  PubMed  CAS  Google Scholar 

  3. Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4:49–60

    Article  PubMed  CAS  Google Scholar 

  4. Tjernberg LO, Näslund J, Lindquist F et al. (1996) Arrest of b-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271:8545–8548

    Article  PubMed  CAS  Google Scholar 

  5. Tenidis K, Waldner M, Bernhagen J et al. (2000) Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J Mol Biol 295:1055–1071

    Article  PubMed  CAS  Google Scholar 

  6. Sciarretta KL, Gordon DJ, Meredith SC (2006) Peptidebased inhibitors of amyloid assembly. Methods Enzymol 413:273–312

    Article  PubMed  CAS  Google Scholar 

  7. Kapurniotu A, Schmauder A, Tenidis K (2002) Structurebased design and study of non-amyloidogenic, double Nmethylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol 315:339–350

    Article  PubMed  CAS  Google Scholar 

  8. Tatarek-Nossol M, Yan LM, Schmauder A et al. (2005) Inhibition of IAPP amyloid fibril formation and apoptotic cell death by a designed IAPP amyloid core-containing hexapeptide. Chem Biol 12:797–809

    Article  PubMed  CAS  Google Scholar 

  9. Kapurniotu A, Bernhagen J, Brunner H (1997) Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie ihre Verwendung bei der Alzheimerschen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien. DE-A1 197 25 619

  10. Westermark P, Andersson A, Westermark GT (2011) Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91:795–826

    Article  PubMed  CAS  Google Scholar 

  11. Schmitz O, Brock B, Rungby J (2004) Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53:233–238

    Article  Google Scholar 

  12. Yan LM, Tatarek-Nossol M, Velkova A et al. (2006) Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc Natl Acad Sci USA 103:2046–2051

    Article  PubMed  CAS  Google Scholar 

  13. Li L, Hölscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56:384–402

    Article  PubMed  CAS  Google Scholar 

  14. O’Nuallain B, Williams AD, Westermark P et al. (2004) Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 279:17490–17499

    Article  PubMed  Google Scholar 

  15. Yan LM, Velkova A, Tatarek-Nossol M et al. (2007) IAPP mimic blocks Ab cytotoxic self-assembly: cross-suppression of amyloid toxicity of Ab and IAPP suggests a molecular link between Alzheimer’s disease and type II diabetes. Angew Chem Int Ed Engl 46:1246–1252

    Article  PubMed  CAS  Google Scholar 

  16. Andreetto E, Yau LM, Tatarek-Nossol M et al. (2010) Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association. Angew Chem Ed Engl 49:3081–3085

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fachgebiet Peptidbiochemie, TU München, München, Germany

    Aphrodite Kapurniotu

  2. Fachgebiet Peptidbiochemie, Technische Universität München, Emil-Erlenmeyer-Forum 5, D-85354, Freising, Germany

    Aphrodite Kapurniotu

Authors
  1. Aphrodite Kapurniotu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aphrodite Kapurniotu.

Additional information

Aphrodite Kapurniotu Jahrgang 1961. 1979–1985 Chemiestudium an den Universitäten Athen und Tübingen. 1990 Promotion an der Universität Tübingen. 1990–1992 wissenschaftliche Angestellte an der Universität Tübingen. 1992–1994 Postdoktorandin an der Rutgers University, NJ, USA. 1994–1995 Senior Scientist am Picower Institute for Medical Research, NY, USA. 1994–2007 Gruppenleiterin an der Universität Tübingen und der RWTH Aachen. 2001 Habilitation im Fach Biochemie an der Universität Tübingen. 2006 Ernennung zur apl. Professorin RWTH Aachen. Seit 2007 Professorin für Peptidbiochemie an der TU München.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kapurniotu, A. Strategien zur Inhibition der Protein-aggregation bei Amyloidkrankheiten. Biospektrum 18, 734–736 (2012). https://doi.org/10.1007/s12268-012-0255-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12268-012-0255-z

Search

Navigation